PHATHOM PHARMACEUTICALS, INC. Financials Phathom Pharmaceuticals, Inc.
Equities
PHAT
US71722W1071
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.04 USD | +2.87% |
|
+9.37% | +9.97% |
| 05-03 | Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target | MT |
| 03-07 | Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 763.8 | 935.7 | 595.5 | 461.6 | 522.7 | 587.6 | - | - |
| Enterprise Value (EV) 1 | 542.8 | 697.2 | 501.9 | 402.2 | 279.9 | 392.8 | 497.8 | 698.4 |
| P/E ratio | -2.73 x | -8.56 x | -5.06 x | -2.22 x | -2.32 x | -2.3 x | -3.01 x | -5.64 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | 766 x | 13.6 x | 3.56 x | 1.67 x |
| EV / Revenue | - | - | - | - | 410 x | 9.07 x | 3.02 x | 1.98 x |
| EV / EBITDA | -5.11 x | -5.56 x | -3.73 x | -2.34 x | -1.68 x | -1.47 x | -1.62 x | -4.47 x |
| EV / FCF | -14.8 x | -9.86 x | -3.09 x | -2.73 x | -2.01 x | -1.89 x | -2.72 x | -3.95 x |
| FCF Yield | -6.75% | -10.1% | -32.3% | -36.7% | -49.7% | -53% | -36.8% | -25.3% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 24,527 | 28,166 | 30,276 | 41,144 | 57,253 | 58,524 | - | - |
| Reference price 2 | 31.14 | 33.22 | 19.67 | 11.22 | 9.130 | 10.04 | 10.04 | 10.04 |
| Announcement Date | 20-03-19 | 21-03-30 | 22-03-01 | 23-02-28 | 24-03-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.682 | 43.3 | 164.9 | 352.3 |
| EBITDA 1 | -106.2 | -125.3 | -134.6 | -171.8 | -166.7 | -266.5 | -307.3 | -156.1 |
| EBIT 1 | -106.2 | -125.7 | -135.1 | -172.4 | -167.3 | -224.1 | -187.9 | -104.7 |
| Operating Margin | - | - | - | - | -24,532.55% | -517.51% | -113.92% | -29.72% |
| Earnings before Tax (EBT) 1 | -255.1 | -129.1 | -143.9 | -197.7 | -201.6 | -261.4 | -219.8 | -117.7 |
| Net income 1 | -255.1 | -129.1 | -143.9 | -197.7 | -201.6 | -261.4 | -219.8 | -117.7 |
| Net margin | - | - | - | - | -29,558.94% | -603.74% | -133.3% | -33.42% |
| EPS 2 | -11.41 | -3.880 | -3.890 | -5.050 | -3.930 | -4.365 | -3.332 | -1.780 |
| Free Cash Flow 1 | -36.64 | -70.73 | -162.4 | -147.6 | -139.2 | -208 | -183 | -177 |
| FCF margin | - | - | - | - | -20,412.61% | -480.36% | -110.97% | -50.24% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-03-19 | 21-03-30 | 22-03-01 | 23-02-28 | 24-03-07 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | 0.682 | 2.166 | 6.009 | 12.02 | 22.87 | 34.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -33.14 | -33.04 | -37.91 | -45.36 | -42.53 | -46.64 | -30.08 | -31.7 | -35.66 | -69.87 | -60.44 | -61.98 | -58.09 | -51.04 | -44.1 |
| Operating Margin | - | - | - | - | - | - | - | - | - | -10,245.45% | -2,789.92% | -1,031.58% | -483.45% | -223.15% | -127.83% |
| Earnings before Tax (EBT) 1 | -36.66 | -35.83 | -40.66 | -50.92 | -51.09 | -55.05 | -37.81 | -40.96 | -43.24 | -79.57 | -64.47 | -64.76 | -61.96 | -56.97 | -53.7 |
| Net income 1 | -36.66 | -35.83 | -40.66 | -50.92 | -51.09 | -55.05 | -37.81 | -40.96 | -43.24 | -79.57 | -64.47 | -64.76 | -61.96 | -56.97 | -53.7 |
| Net margin | - | - | - | - | - | - | - | - | - | -11,667.01% | -2,975.84% | -1,077.74% | -515.62% | -249.11% | -155.65% |
| EPS 2 | -0.9800 | -0.9500 | -1.070 | -1.330 | -1.320 | -1.330 | -0.8900 | -0.8400 | -0.7600 | -1.390 | -1.208 | -1.155 | -1.117 | -0.9233 | -0.9400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-11-08 | 22-03-01 | 22-05-10 | 22-08-02 | 22-11-08 | 23-02-28 | 23-05-10 | 23-08-10 | 23-11-09 | 24-03-07 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 111 |
| Net Cash position 1 | 221 | 238 | 93.6 | 59.4 | 243 | 195 | 89.8 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.7096 x |
| Free Cash Flow 1 | -36.6 | -70.7 | -162 | -148 | -139 | -208 | -183 | -177 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.13 | 1.04 | 0.33 | 1.04 | 1.63 | 2.43 | 2.44 | 1.08 |
| Capex / Sales | - | - | - | - | 239.59% | 5.61% | 1.48% | 0.31% |
| Announcement Date | 20-03-19 | 21-03-30 | 22-03-01 | 23-02-28 | 24-03-07 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.04
USD
Average target price
22
USD
Spread / Average Target
+119.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.97% | 588M | |
| +25.69% | 47.86B | |
| +46.90% | 41.42B | |
| -3.46% | 40.66B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +28.07% | 12.14B | |
| +0.17% | 12.15B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- PHAT Stock
- Financials Phathom Pharmaceuticals, Inc.
